A pill version of Wegovy removes the injection barrier for many patients, and China's huge population makes regulatory acceptance a genuinely large new market opportunity. Acceptance of the application is a concrete milestone that typically precedes appro

Verdict: a real catalyst, but wait for the bar to complete

This is a genuinely interesting catalyst wrapped in a deteriorating fundamental picture and a trigger that has not yet fired. The strongest support is China's acceptance of the oral Wegovy application (per the Reuters piece from August 27, 2026) landing on a company that still earns a 41.3% operating margin (98th percentile of Health Care peers) and DKK 59.0B in free cash flow — a cash machine waiting on Beijing, not a speculator. The strongest headwind is the idea's own trend: FY2025 revenue grew just 6.4%, free cash flow has fallen roughly 29% over two years, and the stock has already shown a 74.6% peak drawdown with negative skew. Technically, NVO at $47.19 is close — price above the 20-day EMA and holding $47.00 support — but the MACD histogram at -0.21 has not crossed, and the rule set produced zero entries across 1,237 evaluated bars, so this remains a watch-list setup with no validated alternative thresholds after the sensitivity check ran out of time. **Conviction breakdown:** thesis support 65 (real catalyst, but the acceptance headline is already public per Reuters); trade readiness 30 (no triggers in 60 months, no robust parameter alternative); risk quality 50 (2:1 reward-to-risk with a 2.3% stop, but tight support and gap risk around China news); trigger proximity 70 (two conditions met, MACD cross near); fundamentals trend 40 (margins, returns and cash flow all sliding from peak).

Trade now

This is a watch-list setup, not an active signal: the strategy evaluated 1,237 daily bars across 60 months and did not open an entry, so today's job is monitoring levels, not buying. NVO closed at $47.19, and two of the four entry conditions are effectively in place — the close sits just $0.13 above the 20-day EMA at $47.06 (met), and price is above nearest support at $47.00. The blocker is the MACD histogram cross: it stands at -0.21, needing to flip above zero — close, but not there yet. The fourth condition (the day's low touching support while the close holds above it) is a bar-shape requirement that can only be judged on the day it prints. LLY, the secondary leg, is further away. It closed near $1,189, about $21 below its 20-day EMA around $1,210, and its MACD histogram at 16.4 would need to cross above zero from a fresh base, not from this elevated reading — that leg reads as 'far' right now. Focus on NVO as the near-term candidate. Risk is defined if the trigger fires. The percentage-based stop is 2.32% below entry and the take-profit is 4.64% above — a 2:1 reward-to-risk. Structurally, the profit target is nearest resistance at $47.94 (about 1.6% above current price) and the deeper stop reference is the second support at $47.52 — note that support sits unusually tight here, so the fixed percentage exits are likely to govern. Position sizing is capped at 25% of the book with roughly 2.3% risk per trade. What 'wait' means concretely: do nothing until an NVO daily bar closes above $47.06 with the MACD histogram crossing above zero, a low that dips to touch the $47.00 area, and a close back above it. If price instead loses $47.00 decisively, the setup resets and the next support shelf is $46.66. One caveat: the research author flagged the compiled thresholds (particularly the same-bar support-touch requirement) as likely too strict and requested bounded optimization, but that sensitivity run produced no recommended parameter change, so no robust alternative setup has been established — trade the levels as written or stand aside.

A visible China catalyst on top of a fortress P&L

The bull case rests on a concrete, dated catalyst: per the Reuters piece from August 27, 2026, China's drug regulator has accepted Novo Nordisk's application for oral Wegovy. The idea argues that application acceptance typically precedes approval and gives investors a visible multi-week catalyst rather than a one-day pop — and oral delivery removes the injection barrier that has limited GLP-1 adoption, in a market (China) where the population base is genuinely enormous. The fundamentals say Novo can absorb the wait and monetize the win. The company generated DKK 309.1B in FY2025 revenue with an 81.0%…

Scores

• Conviction score breakdown: 51
• Thesis support: 65
• Trade readiness: 30
• Risk quality: 50
• Trigger proximity: 70
• Fundamentals trend: 40

Watch items

• NVO — MACD (12,26,9) histogram
• NVO — Close vs EMA (20)
• NVO — Close vs nearest support
• NVO — Close vs nearest support
• NVO — China regulatory acceptance of oral Wegovy application
• LLY — Close vs EMA (20)
• NVO — Close vs second support
• LLY — Price above EMA (20)
• LLY — MACD (12,26,9) crossed above 0
• LLY — ADX (14) above 15
• LLY — MACD (12,26,9) crossed below 0